All Posts

graft-versus-host-disease-gvhd-treatment
Graft-Versus-Host Disease (GvHD) Treatment Market: A Moving Target For Therapies

Allogeneic HSCT is a mainstay for patients with different hematological malignancies, but it requires immunosuppressive strategies before and after HSCT. However, approximately half (50%) of the patients receiving allogeneic hematopoietic stem cell transplantation (HCT) from a human leukocyte antigen (HLA)-matched ...

Find More

MedTech News for Surmodic, Galvanize, STERIS, Orthofix
Orthofix Launched WaveForm A; BD Entered into Agreement with STERIS; Surmodics’s SurVeil™ Drug-Coated Balloon; Cardio Flow Design’s 4D Flow MRI Blood Flow Analysis Software; Galvanize Therapeutics’s RheOx® System; AWAK and SGH’s Wearable Peritoneal Dialysis Device Trial

Orthofix Launched WaveForm A – 3D Printed Anterior Lumbar Interbody On June 19, 2023, Orthofix Medical Inc., a leading global spine and orthopedics company, launched WaveForm® A, an interbody for Anterior Lumbar Interbody Fusion (ALIF) procedures. For the treatment of patients who require fusion due to degenerat...

Find More

Medical Simulation Market
Exploring How Medical Simulation Is Enhancing the Procedural Competence In The Healthcare Industry?

Simulations play a key role in the healthcare industry and are an essential part of medical training. It holds immense potential to improve patient safety by providing safe environments for practice and skill development to healthcare professionals. Furthermore, it enables the detection and mitigation of errors, wh...

Find More

Pharma News for GSK, Roche, Avita, Ipsen
FDA Extended the Review Period for Momelotinib; FDA Approves Roche’s Columvi; Avita Medical Obtains FDA Approval of RECELL; FDA Approves Odevixibat for ALGS; TME Pharma Receives IND Approval for NOX-A12; Aldeyra’s Phase 3 INVIGORATE‑2 Trial of Reproxalap

GSK Announces Extension of FDA Review Period for Momelotinib After all, GSK will not hear from the FDA this month about its marketing application for momelotinib as a therapy for anemia in myelofibrosis patients. The pharmaceutical company announced that the US Food and Drug Administration has extended the drug'...

Find More

multiple-system-atrophy-treatment
Evolving Landscape of Multiple System Atrophy Treatment: Recent Developments and Future Directions

Multiple system atrophy (MSA) is a rare disease that affects between 15,000 and 50,000 Americans, encompassing men and women of all races. Multiple system atrophy has an unknown cause. The great majority of cases are sporadic, meaning they happen at random. The peak onset of multiple system atrophy occurs between t...

Find More

Gene Therapies for Dystrophic Epidermolysis Bullosa
Will The Burgeoning Gene Therapies Make a Difference in Dystrophic Epidermolysis Bullosa Patients’ Lives?

Dystrophic epidermolysis bullosa (DEB) is an inherited disorder caused by changes in the COL7A1 gene. In this rare condition, blisters form on the skin and the moist inner lining of some organs and body cavities. Depending upon the nature of the inheritance pattern, dystrophic epidermolysis bullosa is divided into ...

Find More

MedTech News for Endologix, SunMed, BD
Centinel Spine’s Prodisc C Match-the-Disc Cervical TDR System; Reflow Medical’s DEEPER OUS Trial; FDA Approval to Endologix’s Detour System; FDA Clearance to Smith+Nephew’s Shoulder Replacement System; SunMed Acquired Avanos’s Respiratory Health Business; BD’s Automate Clinical Flow Cytometry

Centinel Spine® Completed Enrollment in First-of-its-Kind 2-Level IDE Trial Evaluating prodisc® C Match-the-Disc™ Cervical TDR System On June 13, 2023, Centinel Spine®, LLC, a leading global medical device company addressing cervical and lumbar spinal disease by providing the most robust and clinically-pr...

Find More

Facial Implants Market Trends
Facial Implants: Evaluating the Reasons Behind the Growing Demand & Key Factors Driving the Market Growth

Everyone has the desire to look beautiful. It makes oneself feel good and provides immense self-confidence. With the aid of modern technology, we now have cosmetic fixes for issues with our looks. Facial Implants and cosmetic surgeries demand is growing at an immense rate globally. Facial Implants are a type of lon...

Find More

Pharma News for Kyverna, Annovis, Astellas, FibroGen
FDA Fast Track Status to Kyverna’s KYV-101; Annovis’s Phase III Study for Buntanetap; Gilteritinib Demonstrated Benefit in AML Patients; FDA Orphan Drug Designation to DTx Pharma’s DTx-1252; FibroGen’s LELANTOS-1 Phase 3 Clinical Study Result

FDA Grants Fast Track Status to KYV-101 for Refractory Lupus Nephritis Treatment Kyverna Therapeutics announced that the FDA has given Fast Track status to KYV-101, a treatment for patients suffering from resistant lupus nephritis (LN). KYV-101 is an innovative therapy that uses anti-CD19 chimeric antigen recept...

Find More

chronic-kidney-disease-ckd-treatment
Evolving Therapeutics in Chronic Kidney Disease (CKD) Treatment Market

Chronic kidney disease burden and diagnostic barriers Chronic kidney disease (CKD) is a progressive and irreversible ailment characterized by gradual loss of kidney function. It is clinically defined by a glomerular filtration rate of less than 60mL/min/1.73m2 or albuminuria of at least 30mg per 24 hours, or any...

Find More